Apex Bioventures and Dynogen Pharmaceuticals announce definitive merger agreement
Apex Bioventures Acquisition Corp. (AMEX: PEX), a publicly traded special purpose acquisition company with healthcare industry expertise, and
Dynogen Pharmaceuticals, Inc., a privately owned clinical stage biopharmaceutical company focused on gastrointestinal and genitourinary disorders, announced today the signing of a definitive merger agreement.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.